Sight Sciences, Inc. (NASDAQ:SGHT) CTO Sells $13,754.00 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CTO David Badawi sold 5,980 shares of the business's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $2.30, for a total transaction of $13,754.00. Following the completion of the transaction, the chief technology officer now owns 1,836,704 shares of the company's stock, valued at approximately $4,224,419.20. This trade represents a 0.32 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

David Badawi also recently made the following trade(s):

• On Friday, January 17th, David Badawi sold 5,423 shares of Sight Sciences stock. The shares were sold at an average price of $2.78, for a total value of $15,075.94.
• On Wednesday, January 8th, David Badawi sold 3,829 shares of Sight Sciences stock. The stock was sold at an average price of $3.26, for a total value of $12,482.54.
• On Friday, January 3rd, David Badawi sold 3,111 shares of Sight Sciences stock. The shares were sold at an average price of $3.52, for a total value of $10,950.72.

Sight Sciences Stock Performance

Shares of SGHT traded down $0.10 during midday trading on Tuesday, reaching $2.11. 91,285 shares of the stock were exchanged, compared to its average volume of 209,147. Sight Sciences, Inc. has a twelve month low of $2.04 and a twelve month high of $8.45. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74. The company has a market capitalization of $108.31 million, a price-to-earnings ratio of -2.06 and a beta of 2.46. The business's 50-day moving average price is $2.66 and its 200 day moving average price is $3.78.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.01). The firm had revenue of $19.07 million for the quarter, compared to analyst estimates of $18.98 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. During the same period last year, the firm earned ($0.22) EPS. On average, sell-side analysts expect that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.

Institutional Trading of Sight Sciences

Large investors have recently bought and sold shares of the business. KCK LTD. purchased a new position in shares of Sight Sciences during the fourth quarter worth about $15,925,000. Long Focus Capital Management LLC grew its stake in shares of Sight Sciences by 158.8% in the 4th quarter. Long Focus Capital Management LLC now owns 2,238,632 shares of the company's stock valued at $8,149,000 after purchasing an additional 1,373,535 shares during the last quarter. B Group Inc. acquired a new position in shares of Sight Sciences in the fourth quarter valued at approximately $2,291,000. Prosight Management LP increased its holdings in shares of Sight Sciences by 71.1% in the fourth quarter. Prosight Management LP now owns 908,847 shares of the company's stock valued at $3,308,000 after purchasing an additional 377,625 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of Sight Sciences by 654.3% during the fourth quarter. Renaissance Technologies LLC now owns 393,006 shares of the company's stock worth $1,431,000 after purchasing an additional 340,906 shares during the last quarter. Institutional investors and hedge funds own 55.51% of the company's stock.

Wall Street Analyst Weigh In

SGHT has been the topic of several analyst reports. Piper Sandler reduced their target price on shares of Sight Sciences from $5.50 to $3.50 and set a "neutral" rating on the stock in a report on Thursday, March 6th. Lake Street Capital lowered their target price on shares of Sight Sciences from $3.00 to $2.50 and set a "hold" rating for the company in a research note on Thursday, March 6th. Citigroup cut their price target on Sight Sciences from $4.60 to $3.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Needham & Company LLC reaffirmed a "hold" rating on shares of Sight Sciences in a research report on Thursday, March 6th. Finally, UBS Group cut their target price on Sight Sciences from $5.50 to $5.00 and set a "buy" rating on the stock in a research report on Monday, January 27th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $3.83.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.